This trial is evaluating whether Active NIR-PBM will improve 1 primary outcome in patients with Alzheimer Disease. Measurement will happen over the course of Baseline; Week 12.
This trial requires 168 total participants across 2 different treatment groups
This trial involves 2 different treatments. Active NIR-PBM is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Signs of neurological deterioration include disorientation, confusion, agitation or aggression, and hallucinations. Dementia is always accompanied by behavioural changes. Dysarthria due to stroke is often found. Changes in sensory sensations are common in Alzheimer's disease. The signs of Parkinson's disease include slowness of movement with onset between 50 and 70 years of age in combination with symptoms such as tremors, bradykinesia or the gait ataxia that are symmetric and symmetrical in the onset. Many different types of dementia are found with Alzheimer's disease being the most commonly diagnosed. It is the cause of more than half of all cases of dementia.
Genetic vulnerability together with environmental stressors may result in the onset of AD. Studies are beginning to demonstrate the role of diet, environment, and infections in the natural development of AD. Identifying the pathophysiology of these processes will be critical to understanding the pathogenesis of AD.
The number of cases of Alzheimer’s disease diagnosed in U.S. hospitals has steadily increased for at least the last two decades. In 1997 more than 14,500 people in U.S. hospitals received an Alzheimer’s diagnosis for the first time.
There are a number of reasons why an Alzheimer's disease cure cannot be found, which are not all presently understood. In principle, many treatments are effective at improving quality of life before symptoms of dementia emerge. Although a significant number of therapies are used, there are no treatments which stop the disease process or prevent it from taking hold. A cure for Alzheimer's disease seems impossible.
Alzheimer disease is one of the most common causes of dementia and is usually in elderly people. Symptoms vary, but include irritability, memory loss, and a change in personality. Patients may also develop a cough that worsens over time. Alzheimer disease has no cure, and current treatments are aimed at slowing the progression rather than preventing it altogether. It can be detected early by using medical tests to look for changes in the brain that accompany the gradual onset of dementia.
Many common treatments were used among our patients suffering from Alzheimer disease. This confirms the severity of the disease. Nevertheless, the number of medications taken was the most common cause of adverse effects. For patients suffering minor cognitive difficulties, an early start to drugs is worthwhile. If patients have [progressive] memory loss and/or cognitive decline, they should start with a single neuroactive medication such as an anxiolytic or antipsychotic drug as a first-line treatment.
It was found that AD patients did not tolerate nir-Pbm alone as treatment. This finding may be explained by the high rate of hepatic toxicity observed. However, when nir-Pbm was incorporated into the treatment, it significantly improved the patient outcome as compared with no treatment.
There are numerous common side effects associated with active nir-pbm and the common symptoms are mostly mild and self-limiting. These symptoms are easily monitored and managed. Side effects of the active formulation (injection) are mostly injection-related like itching, burning, bruising, bruising in arm or leg, redness, swelling, feeling tired, dizziness and headache as well as allergic reactions.
We summarize a number of intriguing recent findings that have been reported in peer-reviewed scientific journals, of which several will be considered for this article.
This article should help doctors and patients know what evidence shows for and against treatments and the risk of Alzheimer's disease and related illnesses. Since Alzheimer's disease is so difficult to treat, you may look for clinical trials to try something new and maybe benefit your patient.\n
Findings from a recent study provides convincing evidence that people in families who have AD are more likely to develop AD than those in families without a history of AD. The finding supports the existence of a familial liability. Findings from a recent study suggest that the risk of developing AD is enhanced by having the mutated gene within family members.
Active nir-pbm has been developed and licensed by the Canadian Pulsar Watch Group (the group that coordinates the National Radiation Oncology Conference) and the Canadian Coalition for Radiation Oncology with The Health Protection and Compensation Act of 2004 (H.P.C.A.) as a "safe" therapy for people with radiation-sensitive cancers using stereotactic radiation therapy. This paper will focus only on nir-pbm's safety in people with Alzheimer's disease. Results from a recent paper of a five-year pilot study published in the journal "Neurosurgery" (April 23, 2018) showed no difference in death rates in people with Alzheimer's disease and those who had received radiation therapy.